Results 201 to 210 of about 124,170 (327)

LCN2‐ACOD1 Signalling Affects the Post‐Injury Regeneration of Skeletal Muscle Through Mediating Ferroptosis

Cell Proliferation, EarlyView.
LCN2 mediates the suppression of C2C12 myoblast proliferation and myotube formation via erastin‐induced ferroptosis. Mechanistically, the LCN2‐ACOD1 axis regulates skeletal muscle growth via mitochondria‐associated ferroptosis, providing a theoretical basis for the prevention and therapy of muscle‐related diseases.
Xiaojing Hao, Hongwei Shi, Di Wu, Rui Liang, Tong Zhao, Wen Sun, Yue Wang, Xiuju Yu, Xiaomao Luo, Yi Yan, Jiayin Lu, Haidong Wang, Juan Wang   +12 more
wiley   +1 more source

Locked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF. [PDF]

Front Pharmacol
Li J, Wu X, Yang Y, Mao R, Li Z, Zhang X, Wei W, Wang W, Li H, Zhou H, Yang C.   +10 more
europepmc   +1 more source

Status quo and future developments in the diagnosis and treatment of hereditary angioedema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE) is a rare hereditary disease characterized by edema, which can be life‐threatening in case of swelling in the larynx. The most common form of HAE is caused by a mutation of the SERPING1 gene and is characterized by a deficiency (type I) or loss of function (type II) of the C1 inhibitor (C1‐INH), leading to excessive ...
Andreas Recke
wiley   +1 more source

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

European Journal of Clinical Investigation, EarlyView.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo, Giuliano Cassataro, Stefano Ministrini, Simon F. Stämpfli   +3 more
wiley   +1 more source

Harnessing BET-Bromodomain Assisted Nuclear Import for Targeted Subcellular Localization and Enhanced Efficacy of Antisense Oligonucleotides. [PDF]

J Am Chem Soc
Kashyap D, Cadeddu M, Oliver PL, Milne TA, Booth MJ.   +4 more
europepmc   +1 more source

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

, 1996
Ronnie Hanecak, Vickie Brown‐Driver, Maureen Fox, Rumana Azad, S Furusako, Chika Nozaki, Carol M. Ford, Henri Sasmor, Kevin Anderson   +8 more
openalex   +1 more source

Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies

Epilepsia, EarlyView.
Abstract Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease‐targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second‐generation drug candidates ...
Heidrun Potschka, Daniel Pérez‐Pérez
wiley   +1 more source

Targeting FANCM by antisense oligonucleotides in ALT-positive cancers. [PDF]

Mol Ther Nucleic Acids
Tieo G, Bao Ying Lim N, Lim KW, Dröge P, Phan AT, Jeitany M.   +5 more
europepmc   +1 more source

Novel neuropathological observations in an adult with Dravet syndrome

Epilepsia, EarlyView.
Abstract Dravet syndrome (DS) is a developmental and epileptic encephalopathy associated with pathogenic variants in the SCN1A gene. The neuropathological features of adult DS remain poorly understood. We report the postmortem findings of a 55‐year‐old woman with DS due to a confirmed SCN1A pathogenic variant leading to Nav1.1 loss of function ...
Danielle M. Andrade, Anne S. Bassett, Quratulain ZulfiqarAli, Victor S. T. Lira, Nikolai Gil Reyes, M. Carmela Tartaglia, Alfonso Fasano, Gabor G. Kovacs   +7 more
wiley   +1 more source

Topological Switch-OFF and β-Galactosidase-Triggered Switch-ON of Cyclic Antisense Oligonucleotides via CuAAC for Controlled RNA Cleavage. [PDF]

Bioconjug Chem
Miyaji K, Takeuchi K, Seio K.
europepmc   +1 more source